Search results for: “HOLX”

  • Hologic Inc Valuation – March 2019 #HOLX

    Hologic Inc Valuation – March 2019 #HOLX

    Hologic, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

  • Hologic Inc Valuation – June 2018 $HOLX

    Hologic Inc Valuation – June 2018 $HOLX

    Hologic, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

  • Hologic Inc Valuation – Initial Coverage $HOLX

    Hologic Inc Valuation – Initial Coverage $HOLX

    Hologic, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, the poor dividend history, and the high PEmg and PB ratios.

  • Universal Health Services Inc Valuation – April 2019 #UHS

    Universal Health Services Inc Valuation – April 2019 #UHS

    Universal Health Services, Inc. Class B qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the low current ratio.

  • Dentsply Sirona Inc Valuation – March 2019 #XRAY

    Dentsply Sirona Inc Valuation – March 2019 #XRAY

    DENTSPLY SIRONA Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the high PEmg and PB ratios.

  • McKesson Corp Valuation – March 2019 #MCK

    McKesson Corp Valuation – March 2019 #MCK

    McKesson Corporation qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the low current ratio.

  • IDEXX Laboratories Inc Valuation – March 2019 #IDXX

    IDEXX Laboratories Inc Valuation – March 2019 #IDXX

    IDEXX Laboratories, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history, and the high PEmg and PB ratios.

  • Charles River Laboratories International Inc Valuation – August 2018 $CRL

    Charles River Laboratories Intl. Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

  • Surmodics Inc Valuation – August 2018 $SRDX

    Surmodics Inc Valuation – August 2018 $SRDX

    SurModics, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the small size, insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

  • Conmed Corp Valuation – August 2018 $CNMD

    Conmed Corp Valuation – August 2018 $CNMD

    CONMED Corporation is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.